IntuitionLabs

INTUITIONLABS / RESEARCH & PRACTICAL GUIDANCE

Syneos Health CRM: Dynamic Assembly & Key Technologies

> Build practical AI for pharma and biotech with IntuitionLabs. We help life-science teams turn complex information and workflows into useful software, governed knowledge systems and AI tools.

Published by IntuitionLabs · 2026-01-11 · syneos health crm · dynamic assembly · life sciences crm · veeva commercial cloud · hcp engagement · pharma crm · microsoft dynamics 365

Original article: https://intuitionlabs.ai/articles/syneos-crm-dynamic-assembly



In this article

1. Executive Summary
2. Introduction and Background
3. Syneos Health Overview: The Need for a Dynamic CRM
4. CRM and Customer Experience in Life Sciences
5. Syneos Health's Dynamic Assembly Strategy
6. Syneos Health CRM Ecosystem and Partnerships
7. Implementation and Technical Details
8. Data, Analytics, and Evidence-Based Insights
9. Real-World Examples and Case Illustrations
10. Implications and Future Directions
11. Conclusion

[Revised May 3, 2026] This report has been updated to reflect Syneos Health's September 2023 take-private acquisition by Elliott Investment Management, Patient Square Capital, and Veritas Capital ($7.1B), leadership changes (Michelle Keefe became CEO in April 2022; Costa Panagos was appointed CEO in October 2024), Indegene's May 2024 IPO on India's NSE/BSE, and Veeva Systems' ongoing migration of its CRM from the Salesforce platform to Veeva Vault CRM (target completion 2030).

Executive Summary

Syneos Health, a leading biopharmaceutical solutions provider, employs a **dynamic, best-of-breed CRM strategy** to revolutionize customer engagement in the life sciences industry. Rather than relying on a single vendor's legacy system, Syneos Health's "**Dynamic Assembly®**" approach integrates multiple agile technologies (e.g. Veeva Commercial Cloud, Microsoft Dynamics 365, Indegene's Omnipresence/Exeevo platforms, Azure AI, etc.) into a unified customer experience platform (www.sec.gov) (www.veeva.com). These interoperable platforms provide comprehensive HCP (healthcare professional) and HCO (healthcare organization) data (Syneos's 2020 10-K separately describes a proprietary database of approximately 700,000 industry professionals that supports project ramp-up, i.e. staffing, rather than an HCP marketing list (www.sec.gov), and via Veeva OpenData gains access to ~16 million global HCPs/HCOs (www.veeva.com)), omnichannel engagement tools (field CRM, digital meetings, email, etc.), and embedded analytics/AI for real-time insights. By activating end-to-end **HCP experiences** and unifying CRM with omnichannel technology and data science, Syneos enables smarter commercial interactions, better aligning with HCP needs and preferences (www.syneoshealth.com) (www.syneoshealth.com). This next-gen CRM strategy, underpinned by Microsoft and Veeva technologies, has been explicitly designed to yield **"actionable insights and better commercial experiences, with improved return on investment,"** as then-Syneos CEO Alistair Macdonald stated in 2020 (Macdonald was succeeded by Michelle Keefe in April 2022; in October 2024 Syneos appointed Costa Panagos CEO, succeeding Colin Shannon (www.syneoshealth.com)) (www.biospace.com).

In 2020, Syneos announced offerings spanning both *Veeva Commercial Cloud* solutions (on which ~80% of pharma sales forces run (www.zensar.com)) and *Microsoft-based* life-sciences CRM solutions (via its January 2020 strategic collaboration with, and minority investment in, Indegene Omnipresence, a business that later operated as Exeevo; Valsoft acquired Exeevo in December 2024 (www.valsoftcorp.com), and this report found no public statement of Syneos's role after that sale) (www.prnewswire.com) (exeevo.com). This means Syneos can tailor CRM implementations to each customer's needs while leveraging the industry's most comprehensive HCP data and multichannel tools (www.veeva.com) (www.veeva.com). For example, Syneos joined with Veeva in 2020 to "*strengthen relationships with HCPs, expand global reach faster, and make better decisions using industry's most comprehensive, accurate data*" (www.veeva.com). The Symbiosis of these platforms supports Syneos's claim of being *"data dynamic and ahead of the curve"*, enabling clients to navigate complex regulatory and competitive pressures with a unified, AI-enhanced CRM solution (www.biospace.com) (www.sec.gov).

This report provides an in-depth analysis of Syneos Health's dynamic CRM strategy. It covers the historical evolution of CRM in the life sciences and Syneos's role in that evolution, the architecture of its open-source-agnostic infrastructure ("Dynamic Assembly"), detailed descriptions of the CRM technologies and partnerships Syneos employs (Veeva, Microsoft Dynamics/Omnipresence/Exeevo, Azure AI, etc.), quantitative evidence of market trends, and expert perspectives (industry analysts, Syneos executives, etc.). We also discuss real-world applications and implications, including synergies in data integration, sales force automation, regulatory compliance, and future directions (AI-driven personalization, omnichannel orchestration, etc.). The report includes comparative tables and multiple citations to ensure that all key claims are evidence-based and up-to-date. Specifically, we document synergies between Syneos and CRM leaders (Indegene, Microsoft, Veeva), the benefits of CRM modernization (faster launches, improved ROI), and alignment with industry-wide trends (digital engagement, AI-augmented salesforces (www.pharmalive.com) (www.ey.com)).

Key findings include:

- **Open, Adaptive Architecture ("Dynamic Assembly")** – Syneos deliberately avoids lock-in by integrating best-of-breed platforms in an open, source-agnostic way (www.syneoshealth.com) (www.sec.gov). This allows each customer's CRM solution to be *"asset-customized"* with both proprietary and third-party data (www.sec.gov) (www.sec.gov), and easily updated with new tools as they arise (e.g. generative AI, new data services).
- **Unified HCP Engagement** – Through its 2020 collaboration with, and minority investment in, Indegene Omnipresence (built on Microsoft Azure and Dynamics 365; the business later operated as Exeevo, which Valsoft acquired in December 2024) (www.prnewswire.com) (exeevo.com), plus the Veeva Commercial Cloud suite (www.veeva.com) (www.veeva.com), Syneos provides clients with a single infrastructure for all HCP touchpoints – from face-to-face to digital meetings, email, chat, and content portals – enriched by comprehensive profile data. This unified platform moves *beyond traditional CRM* to a full Customer Experience Management (CXM) paradigm (www.syneoshealth.com) (www.syneoshealth.com).
- **AI and Analytics Integration** – Syneos leverages advanced analytics and AI (via Azure Synapse, Indegene analytics, KX Data Timehouse, etc.) to derive insights from multi-source data (www.biospace.com) (www.syneoshealth.com). For example, the omni-platform can cluster HCP preferences and predict channel effectiveness, enabling *"insights-driven experiences"* that yield higher

impact and satisfaction (www.syneoshealth.com) (www.biospace.com). This aligns with industry consensus that AI will dramatically transform CRM (shifting from simply data tracking to real-time “GPS” guidance for pharma sales (www.ey.com) (www.pharmalive.com)).

- **Business Impact** – By combining Syneos’s domain expertise with these technologies, the company expects to improve campaign performance, shorten launch timelines, and demonstrate value (e.g. optimizing site selection with analytics) (www.syneoshealth.com) (www.veeva.com). Syneos’s dynamic CRM approach addresses pain points cited by industry analysts: reputedly low CRM maturity (www.ey.com), a decline in traditional rep access (www.ey.com) (www.pharmalive.com), and rising value-based engagement demands (www.biospace.com).

Overall, Syneos Health’s dynamic CRM strategy is designed to be **future-proof, data-driven, and patient/HCP-centric**. It anticipates ongoing shifts – such as more specialty drugs, hybrid sales channels, and AI-driven personalization – by building an architecture that can rapidly incorporate new capabilities. In the context of a rapidly digitizing life sciences market, this approach positions Syneos and its clients to stay competitive in delivering smarter customer relationships now and in the future (www.syneoshealth.com) (www.ey.com). All claims and projections in this report are drawn from credible sources such as Syneos’s SEC filings, press releases, partner announcements, and industry analyses, ensuring a rigorous evidence-based perspective.

<!-- Executive summary ends -->

Introduction and Background

Customer Relationship Management (CRM) systems are the cornerstone of modern commercialization strategies in the pharmaceutical and biotech industries. They encompass the processes and technologies by which companies **record, manage and analyze interactions with healthcare professionals (HCPs) and other stakeholders**, with the goal of improving sales effectiveness and customer satisfaction (www.ey.com) (www.veeva.com). Unlike CRM in many other sectors, pharma CRM must account for unique challenges: complex regulatory compliance (HIPAA, GDPR, industry codes), lengthy product life cycles, and a shifting mix of in-person and digital engagement. Traditionally, CRM in life sciences focused on field forces and key account management, often via on-premises software. However, a decade ago the industry began moving to cloud-based, industry-specific CRM (e.g. Veeva) that could better handle scale and data integration.

In this context, **Syneos Health** emerged as an early adopter of advanced CRM capabilities. Formed in 2018 by the merger of INC Research and inVentiv Health, Syneos quickly positioned itself as *“the only fully integrated biopharmaceutical solutions organization”* (www.syneoshealth.com) (www.prnewswire.com), offering end-to-end services from clinical development through commercialization across >110 countries (www.prnewswire.com). Syneos’s value proposition has been to blend therapeutic and commercial expertise with modern technologies to accelerate drug development and launch. The company’s leadership, including Michelle Keefe (CEO from April 2022, succeeding Alistair Macdonald; Costa Panagos has been CEO since October 2024), emphasized digital transformation: for example, in 2023 Syneos announced a multi-year collaboration with Microsoft to embed AI into clinical and commercial analytics (Azure ML, OpenAI-derived tools) (www.syneoshealth.com). This transfusion of data science underscores Syneos’s commitment to **data-driven decision-making** in all phases of product lifecycles.

Coinciding with these trends, Syneos Health conceptualized **“Dynamic Assembly”**, a strategic approach to technology. Rather than building one monolithic IT system, Syneos maintains an *open, source-agnostic architecture*, curating a **network of best-of-breed partners and platforms** (www.syneoshealth.com) (www.biospace.com). As the company explains on its website, *“the right strategy to leverage data and technology for success is via an open, source-agnostic and highly flexible architecture… We call this Dynamic Assembly.”* (www.syneoshealth.com). In practice, Dynamic Assembly means Syneos can tailor solutions to each client’s needs — matching, for example, some customers with Veeva CRM, others with Microsoft-based solutions — and quickly integrate new tools without being tied to legacy in-house systems (www.syneoshealth.com) (www.sec.gov).

This report will systematically explain how Syneos Health implements CRM under the Dynamic Assembly paradigm. We begin by summarizing the **historical context** and **industry drivers** behind modern pharma CRM: regulatory requirements, shifts to specialty medicine, digital engagement trends, and analyst views on CRM transformation (www.zensar.com) (www.ey.com). We then profile Syneos Health’s corporate strategy and its proprietary CRM assets (Syneos One®, Catalyst network, etc.), with an emphasis on commercial deployment. Next, we detail Syneos’s current CRM and CXM ecosystem: its equity investments and partnerships with Indegene (Omnipresence, Exeevo) and Veeva, plus its collaboration with Microsoft and other tech firms. We analyze the specific **technologies and methodologies** in play (e.g. Dynamics 365 CRM, Power Platform, AI bots, master data management). The report includes data on market adoption (e.g. Veeva share, HCP database sizes), outcomes such as launch acceleration and ROI improvements, and expert commentary from industry research. Where possible, real-world or hypothetical case examples illustrate the benefits of Syneos’s approach. Finally, we discuss the implications for stakeholders and future directions — including the rise of AI-driven CRM, evolving HCP expectations, and how Syneos’s model may shape the landscape going forward.

Throughout, all assertions are **evidence-based and cited**: using Syneos’s public filings and press releases (www.sec.gov) (www.syneoshealth.com), partner announcements (www.prnewswire.com) (exeevo.com), industry analyses (www.ey.com) (www.zensar.com), and relevant market data (www.veeva.com) (www.zensar.com). This comprehensive treatment should provide a reader with a clear understanding of *what* Syneos Health’s Dynamic CRM is, *how* it works, why it matters, and where it is headed.

Syneos Health Overview: The Need for a Dynamic CRM

Syneos Health (formerly Nasdaq: SYNH; taken private in September 2023 by a consortium led by Elliott Investment Management, Patient Square Capital, and Veritas Capital in a $7.1B transaction) provides integrated development and commercialization services to biopharma companies (www.prnewswire.com). Its offerings span clinical trial design, clinical operations, and a range of **commercial services** (sales force outsourcing, marketing, patient support, etc.). As such, Syneos sits at the intersection of drug development and product launch. This means it must engage both with clinical stakeholders (investigators, patients) and with healthcare professionals (physicians, pharmacists) who influence product adoption. Effective CRM is therefore core to its business: Syneos’s 2020 10-K reported a staff of more than 25,000 employees and contingent workers across all of its clinical and commercial businesses; its commercial teams deliver clients’ brand messaging and collect market intelligence.

Pharma CRM has special characteristics: it must track interactions with **healthcare providers (HCPs)**, which often requires integrating data from multiple sources (medical literature, promotional events, digital channels, prescription databases) while complying with regulations (e.g. the EFPIA Code, Anti-Kickback statutes, HIPAA). Companies frequently maintain **HCP master databases** from third parties (like IQVIA, Veeva OpenData, etc.) and link them to internal sales activity records. The goal is a *single customer view* that informs customer segmentation, detailing strategies, and compliance auditing.

Here, Syneos's approach addresses two critical demands:

1. **Comprehensive Data Access:** Syneos's 2020 10-K describes a *proprietary database* of approximately 700,000 industry professionals, which it cites as supporting efficient project ramp-up (staffing); it is not described as an HCP marketing database. (www.sec.gov). For HCP/HCO customer data, partner-provided sources matter most (for example, its partnership with Veeva opens access to ~16 million global HCP/HCO records (www.veeva.com)), supporting customer modeling at a granular level. The 2020 10-K highlights this: *"Harmonizing diverse data via Dynamic Assembly to create 'asset-customized' data"* (www.sec.gov).
2. **Flexible Technology Integration:** Recognizing no single vendor dominates every aspect of life sciences CRM, Syneos chose an open ecosystem. As its website states, Dynamic Assembly is *"source agnostic"* so the firm isn't forced to bend a legacy system to novel tasks. In practice, Syneos "partners with best-of-breed technology and data providers – and leverages our clinical and commercial insights… to design solutions" tailored to each protocol or product (www.sec.gov). For example, for one client a Veeva CRM solution with strong account-data capabilities may be ideal; for another, a Microsoft-based omnichannel solution might fit better. This agility contrasts with older models (e.g. a single global CRM platform) and is meant to accelerate deployment: *"instead of being forced to bend legacy in-house assets… we can address each customer, trial protocol and product launch quickly"* (www.syneoshealth.com).

The impetus for this dynamic approach includes industry-wide pressures. According to EY and others, **pharma sales models are undergoing a fundamental shift** (www.ey.com) (www.zensar.com). Historically, drug promotion relied heavily on face-to-face sales rep visits. However, HCPs have less time and more information channels, so in-person interactions have declined for years (www.zensar.com) (www.ey.com). The COVID-19 pandemic further forced a pivot to virtual engagement (tele-detailing, e-mail, webinars). Analysts note that, going forward, **multi-channel orchestration** is critical: "sales reps will be increasingly supported" by data and AI (www.pharmalive.com), and successful reps will become *"omnichannel orchestrators,"* enabled by CRM data and generative AI bots (www.pharmalive.com). In short, the industry expects CRM to evolve from simple tracking into an intelligent engagement platform.

Syneos has internalized these trends. Union of their Dynamic Assembly strategy with CRM modernization means that **CRM at Syneos is not static**. Instead, it is a continuously evolving bundle of services. Their CEO emphasized that Omnipresence and other tools will *"enable customers to harness data… to realize better commercial experiences, with improved return on investment."* (www.biospace.com). By investing in partnerships (Indegene, Veeva, Microsoft, KX, etc.), Syneos is essentially outsourcing the R&D of next-generation CRM to specialized leaders, yet tightly integrating those tools into its service offer (www.veeva.com) (exeevo.com).

In summary, the dynamic needs of pharmaceutical commercialization — large, mobile sales teams; a blend of scientific and promotional communications; stringent compliance; and rapidly advancing technology — have driven Syneos to adopt an *ecosystem* approach to CRM. The **Dynamic Assembly** strategy and its technology network enable Syneos to remain nimble, deploying the latest CRM best practices and platforms for every client engagement. The sections that follow delve into the specific platforms, partnerships, and processes that make up Syneos's CRM solution.

CRM and Customer Experience in Life Sciences

Evolution of Pharma CRM

The life sciences industry has historically been slower to adopt cutting-edge CRM than other sectors, due to its complex regulations and customer base. For decades, pharma's customer engagement model centered on a distributed sales rep force armed with product samples and slide decks – essentially an analog approach. Automated CRM systems first emerged in the 1990s and 2000s to digitize rep call reports and contact management. Early solutions often repurposed generic CRM software (like Siebel CRM or Oracle) for life sciences use, but these lacked industry-specific functionality.

By the late 2000s, life sciences began to see *"the arrival of dedicated life sciences CRM systems"* (www.ey.com). For example, Veeva Systems launched a cloud-based CRM tailored to pharmaceutical needs, and other players (including a Salesforce Life Sciences Cloud, Microsoft Dynamics 365 Life Sciences templates, etc.) entered the market. These systems incorporated HCP databases, compliance modules, and multi-channel campaign tools. However, even as late as early 2020s, EY notes that the industry's CRM maturity remains relatively low (www.ey.com), in part because internal processes and siloed data have held companies back.

The **COVID-19 pandemic** was a major accelerant of CRM evolution. With in-person rep access largely shut down, companies were forced to engage HCPs virtually. According to a 2024 analysis, *"for years leading up to 2020 there was an evolving trend of declining in-person interactions… COVID-19 accelerated that trend with more emphasis on digital/omnichannel engagement options and mobile field intelligence solutions."* (www.zensar.com). Pharma went full digital: video calls, emails, webinars, virtual conferences, tele sales and support. This shift also heightened the need for unified CRM: digital touchpoints generate rich engagement data, but if scattered across isolated channels, these data cannot deliver a seamless customer experience.

Accordingly, **next-generation CRM** in life sciences is moving toward a holistic Customer Experience Management (CXM) paradigm. The traditional definition of CRM – a sales and marketing tool – is expanding. Today's pharma CRM platforms aspire to *orchestrate the "end-to-end" HCP journey* across pre-sales, sales, and post-sales interactions (www.syneoshealth.com) (www.pharmalive.com). For example, rather than separately planning a rep call and an email blast, a unified CX system tracks the entire sequence of HCP engagements and tailors each subsequent interaction. This shift is evident in marketing: one analyst notes that *"CRM is effectively the industry's GPS"* to understand and steer customer relationships (www.ey.com).

Two related trends characterize modern CRM/CXM in life sciences:

- **Data-Driven Personalization:** By integrating multiple data sources (prescriptions, surveys, event attendance, medical records, etc.), CRM can develop a 360° profile of each HCP or account. ML/AI techniques can then identify the next-best action or channel for engagement. In practice, this means pharma can send HCPs more relevant content (e.g. specific disease updates) at the optimal time. Syneos's platforms lean into this idea by supplying analytics/AI layers (Azure AI, Indegene analytics, KX engines) that surface insights from combined data (www.syneoshealth.com) (www.clinicaltrialsarena.com).
- **Omnichannel Orchestration:** HCPs now expect to interact on their preferred channels (in-person, email, phone, video, chat apps, etc.). A unified CRM ensures these channels are coherent: for instance, notes from a field rep visit should inform the digital marketing system and vice versa. Syneos's solution explicitly unifies CRM with omnichannel engagement; its Omnipresence/Exeevo platform and Veeva CRM both claim to tie together *"personal and digital channels"* under one roof (www.syneoshealth.com) (www.veeva.com).

Industry experts emphasize that CRM strategy should focus on **customer outcomes** rather than platform features. An EY study on next-gen CRM urges companies to ask "what CRM is for – how can we use it more effectively?" (www.ey.com). In other words, choosing a platform (Veeva vs. Salesforce vs. Dynamics) is less important than defining the customer journey it must support. That insight underlies Syneos's approach: by not being wedded to one vendor, it can select the right tools for each client's customer-base and go-to-market strategy.

To sum up, CRM in life sciences has evolved from siloed rep-based tools to the new paradigm of omnichannel CXM with strong analytics. Syneos Health's strategy recognizes and exploits this evolution (Table 1). As an example, the company's investments in cloud and AI accelerate the transition from legacy CRM (static lists, limited reporting) to AI-powered customer orchestration.

Table 1: Key CRM/CXM Capabilities and Syneos Health's Approach	**Syneos Health Implementation**	**Notes and References**
Unified HCP/HCO Data – master reference of providers and institutions	- Third-party HCP/HCO reference data (e.g. Veeva OpenData ~16M HCP/HCO); Syneos's separate ~700K-professional database is described in its 10-K as a staffing resource (www.sec.gov) (www.veeva.com). - Master data management via Veeva Network, CRM engagement logs.	Rich, up-to-date HCP profiles support segmentation and compliance. (www.veeva.com)
Omnichannel Engagement – multi-channel campaign and interaction management	- Veeva Commercial Cloud: multichannel CRM (field rep meetings, approved email, digital channels) (www.veeva.com). - Indegene Omnipresence/Exeevo: unified CX platform integrating CRM, medical, events, marketing automation (www.prnewswire.com) (exeevo.com).	Enables marketing/sales teams to coordinate across in-person calls, email, webinars, etc. (www.syneoshealth.com) (www.syneoshealth.com).

Table 1: Key CRM/CXM Capabilities and Syneos Health's Approach	Syneos Health Implementation	Notes and References
AI/Advanced Analytics – insights from combined data sources	- Azure Synapse Analytics and other Azure services in Syneos's analytics platform (2023 Microsoft collaboration) (www.prnewswire.com). - Collaboration with KX for big data analytics (patient simulations, RWE) (www.clinicaltrialsarena.com). - Customized dashboards and AI bots for reps (e.g. next-best-action suggestions (www.zensar.com) (www.pharmalive.com)).	Syneos's platforms claim to deliver "insights-driven experiences" with ML that aligns activities to HCP needs (www.syneoshealth.com) (www.biospace.com). Emerging area.
Flexible, Best-of-Breed Integration – open, vendor-agnostic architecture	- **Dynamic Assembly®** model: source-agnostic, adaptable platform architecture (www.syneoshealth.com) (www.sec.gov). - Announced collaborations include Veeva (2020), Indegene Omnipresence (2020; the business later operated as Exeevo and was acquired by Valsoft in December 2024), Microsoft (2023) and KX (2023) (www.prnewswire.com) (www.veeva.com).	Quickly add/change solutions per client or evolving technology (e.g. incorporating generative AI CRM bots (www.zensar.com)) without legacy constraints. (www.sec.gov)
Compliance and Auditability – meeting regulatory requirements	- Standard modules in Veeva Commercial Cloud (audit trails, customer consents) (www.veeva.com). - Electronic logs of all rep and digital contact events. - Centralized data helps demonstrate compliance.	Critical in pharma; platform features support, but do not by themselves establish, compliance: each sponsor and service provider remains responsible for its own risk analysis, agreements and controls.
Outcome-focused Insights – ROI and customer satisfaction	- Platforms underpinned by analytics meant to improve ROI (as per executive statements (www.biospace.com)). - Continuous feedback loops: use CRM analytics to refine strategies.	Improving speed-to-market and impact is a stated goal — e.g., Syneos reports expect *"improved return on investment"* (www.biospace.com).

Source: Author's analysis; Syneos Health press and filings (www.syneoshealth.com) (www.sec.gov) (www.veeva.com) (exeevo.com); industry reports (www.ey.com) (www.zensar.com).

Syneos Health's Dynamic Assembly Strategy

Central to Syneos Health's CRM capabilities is its **Dynamic Assembly®** philosophy. This section describes what this entails and how it underpins the CRM approach.

Concept and Rationale

Syneos Health explicitly frames Dynamic Assembly as an **"open, source-agnostic and highly flexible architecture"** intentionally designed to keep the company nimble (www.syneoshealth.com). In essence, Syneos treats technology and data tools as modular components that can be swapped or combined depending on demand. This stands in contrast to legacy models where a company builds proprietary systems that evolve slowly. Syneos argues that life sciences requirements (varied products, trial protocols, regional markets) are too specific for one-size-fits-all software. Instead, Dynamic Assembly means:

- **Openness:** Syneos does not limit itself to a single CRM vendor. It will use Veeva, Microsoft solutions, or other niche platforms as appropriate. As one executive put it, Dynamic Assembly allows addressing each customer's needs *"rather than being forced to bend legacy in-house assets to a task they weren't originally designed to deliver."* (www.syneoshealth.com).
- **Source Agnosticism:** Whether data or software comes from Syneos's own systems or external providers, it can be integrated. This includes data from Syneos's internal databases (patients, sites, HCPs) and from partners (like Veeva OpenData, KX, etc.) (www.sec.gov) (www.veeva.com).
- **Best-of-Breed Collaboration:** Syneos builds a curated network of specialized partners. For example, Syneos engages with technology leaders across categories: master data (Veeva Network), CRM (Veeva CRM, Dynamics 365), omnichannel marketing (Indegene Omnipresence), AI analytics (Microsoft Azure, KX), etc. This *"broad and growing group of best-of-breed data and technology collaborators"* is itself dubbed the Dynamic Assembly network (www.biospace.com).
- **Fit-for-Purpose Solutions:** The intention is that the end-solution is always tailored. Syneos's annual report explicitly notes that Dynamic Assembly lets them *"create 'asset-customized' insights"* and *"quickly address the nuances of each customer challenge, including trial protocol and product launch."* (www.sec.gov). In other words, every CRM implementation is customized to the therapy area, market dynamics, and technology preferences of that specific client.

Importantly, Dynamic Assembly is described as **capital-efficient**. By partnering rather than building everything in-house, Syneos can leverage external R&D. Simultaneously, Syneos integrates its decades of therapeutic and commercial experience into these platforms. The 10-K emphasizes: *"Our open, source-agnostic... architecture focuses on integrating quality data with the insights and best practices we have established during our decades of developing and commercializing biopharmaceutical products."* (www.sec.gov). This melding of external tech and internal expertise is a core Syneos strategy.

Syneos One and Catalyst Network

While Dynamic Assembly spans data and technology choices, Syneos has branded its integrated approach to customers. In past filings, Syneos described *"Syneos One"*, an internal methodology combining expert staff, patented processes, and analytics to manage drug development from lab through launch. Within this, CRM tools fall under the commercial capabilities. Likewise, the **Catalyst Clinical Network** supports clinical trial outreach. Dynamic Assembly complements these by ensuring that commercial engagement and trial operations share a data foundation.

The Syneos website also references the **Catalyst** and **Commercial Acceleration** services, which are enabled by CRM/data integration. Though not CRM per se, these highlight that Syneos already coordinates large field teams and digital programs across clients – all of which rely on robust CRM infrastructure. For example, the "Engagement Center" service (Syneos's in-house omnichannel contact center) explicitly markets digital/customer support programs and emphasizes *"insights from across the product development lifecycle"* (www.syneoshealth.com). Such omnichannel programs would feed back into CRM data (e.g., teasing out patient support inquiries, medical inquiries, complaints) to improve future rep outreach.

Documented Benefits of Dynamic Assembly

Syneos management frequently links Dynamic Assembly to key performance gains. In earning calls and releases, they claim faster timelines and higher quality. For instance, in 2020 the company noted that the OmniPresence platform (a Dynamic Assembly element) *"will enable customers to harness data to provide actionable insights and realize better commercial experiences, with improved return on investment."* (www.biospace.com). Another example: Syneos's volumetric press mentions *"Site and patient burden [is eased], expand [ing] patient populations, and improve patient diversity",* attributing these to their decentralized operations powered by Dynamic Assembly (www.sec.gov).

While publicly available quantitative metrics are scarce (as with most private partner integrations), Syneos points to internal improvements. In the Veeva integration press release, Syneos Commercial president Michelle Keefe explicitly said Veeva's tools will give field reps "the insights they need to plan and execute more effectively," improving rep productivity (www.veeva.com). In short, Dynamic Assembly is pitched not as a marketing buzzword but as a driver of concrete benefits: agility of deployments, depth of insights, and custom solutions tailored to each client.

Syneos Health CRM Ecosystem and Partnerships

Under the Dynamic Assembly umbrella, Syneos has formed strategic collaborations with several **CRM and technology vendors**. The most prominent are Veeva Systems and Indegene (including its subsidiaries Exeevo/Omnipresence), along with a broader alliance with Microsoft. Syneos has also engaged category specialists like KX for data analytics, Adobe for content solutions (via partnerships), and others. Below we detail Syneos's key CRM-related partnerships and investments.

Veeva Commercial Cloud Partnership (2020)

In July 2020, Syneos announced that it would **offer clients Veeva Commercial Cloud** "solutions" as part of its Commercial services. (Note: Since 2022, Veeva Systems has been transitioning its CRM from the Salesforce platform to its own **Veeva Vault CRM**, which became generally available in April 2024; Veeva has guided customers to complete migration to Vault CRM by September 2030, when Veeva CRM on Salesforce reaches end-of-life. Implementations under the Syneos–Veeva partnership are accordingly evolving toward Vault CRM.) (www.veeva.com). Veeva Systems (NYSE:VEEV) is the market leader in pharma cloud CRM, and this partnership was phrased as an expansion of Syneos's Dynamic Assembly network rather than a replacement of anything. Michelle Keefe said at the time: *"Veeva Commercial Cloud gives our field reps and data scientists the insights they need to plan and execute more effectively,"* and *"we are pleased to add these tools to the Syneos Health Dynamic Assembly network, an open ecosystem of best, most agile data and technologies."* (www.veeva.com).

Key Elements of the Veeva Partnership:

- **Veeva Commercial Cloud suite:** This includes Veeva CRM for field force automation, Veeva Compass (analytics), Veeva OpenData (HCP/HCO reference data), Veeva Network (master data hub), and Veeva Approved Email/Engage (digital engagement tools). The press release highlights:

- *Veeva OpenData* – provides Syneos access to ~16M HCP/HCO profiles across 34 countries. This enables more accurate customer profiles and faster campaign targeting (www.veeva.com).
- *Veeva Network* – consolidates and cleans customer master data, giving Syneos a single source of truth for HCP information (www.veeva.com).
- *Veeva CRM Engage/Approved Email* – to drive compliant online meetings and tailored email outreach, integrated with Veeva CRM. (www.veeva.com).
- **Business impact:** The explicit goal was to *"improve performance, reduce risk, and accelerate [our customers'] commercial launches"* (www.veeva.com). Syneos positions these tools as bolstering its field force and marketing services by giving reps reliable data and digital engagement capabilities. Notably, this press release shows how Veeva fits the Dynamic Assembly strategy: Syneos did not buy Veeva, but integrated it. The quote *"we are pleased to add these tools to our Dynamic Assembly network"* (www.veeva.com) implies Syneos might also integrate other tools alongside Veeva.
- **Complementarity with other tools:** Separately, an industry overview notes that Veeva integrates with Microsoft Office and Teams (www.zensar.com), which aligns with Syneos's Microsoft investments (see below). Because Veeva is enterprise-grade and widely adopted (estimated ~80% life sciences CRM market share (www.zensar.com)), providing it ensures Syneos can meet customers who demand it. But importantly, Syneos kept other doors open: it is equally willing to implement MS-based CRM solutions, reflecting its source-agnostic promise.
- **Results and client uptake:** While Syneos has not publicly reported metrics from this partnership, we can infer value. Veeva has stated that its Commercial Cloud aims to unify multichannel engagement in a single system. Syneos's choice to adopt Veeva suggests they expect improved lead management, compliance tracking, and global consistency. For example, Veeva's claim that OpenData lets companies "profile customers faster" and reduce admin time (www.veeva.com), if realized, would shorten pre-launch preparation tasks — a key factor in accelerating launches. Syneos clients thus benefit from both Syneos's field team operations and Veeva's data infrastructure.

Indegene Omnipresence and Exeevo (2020)

In January 2020, Syneos announced a strategic collaboration with, and minority investment in, Indegene Omnipresence, Indegene's SaaS platform business. (Indegene subsequently went public in May 2024 with a ~₹18.4 billion / ~$220M IPO listed on India's NSE and BSE. Exeevo, the business that grew out of Omnipresence, was acquired by Valsoft in December 2024 (www.valsoftcorp.com).) Specifically, Syneos became a strategic collaborator in **Indegene Omnipresence**, said to be a new SaaS CRM/CXM platform for life sciences (www.biospace.com) (www.prnewswire.com). Omnipresence (by Indegene Omnipresence Inc., a business that later operated as Exeevo, whose site republishes the same announcement) was described in PRs as **"next-generation unified customer experience platform for healthcare and life sciences"** (www.prnewswire.com) (exeevo.com). These platforms are verticalized solutions built on Microsoft's ecosystem:

- **Technology Stack:** Omnipresence (later Exeevo) was built in strategic alliance with Microsoft (www.prnewswire.com) (exeevo.com). They leverage **Azure analytics and AI**, **Microsoft Dynamics 365**, **Power Platform** (PowerApps, Flow, etc.), and **Office 365/Teams** for productivity. This gives them deep integration with enterprise Microsoft tools.
- **Capabilities:** The platforms integrate traditional CRM functions (customer master data, sales force automation) with omnichannel engagement (email, events, medical inquiry management, etc.), marketing automation, consumer/patient engagement, and advanced analytics/AI (www.prnewswire.com) (exeevo.com). For example, the Exeevo announcement explicitly mentions managing *"medical, event management, service, [and] customer insights"* in one solution (exeevo.com). Together, these features mirror Syneos's multichannel needs – from KOL (key opinion leader) management to next-best messaging.
- **Strategic Rationale:** By investing in Omnipresence/Exeevo, Syneos gains a foothold in Microsoft-based CXM for life sciences. Syneos CEO commented that Omnipresence is *"an innovative platform, underpinned by Microsoft technologies, to drive intelligent commercial relationships."* (www.biospace.com). The implication is that Syneos can now offer clients a Microsoft-technology alternative to Veeva, suitable especially for customers already in the MS stack. One press release noted that Exeevo is *"designed specifically for life sciences"* and empowers teams *"to deliver a 360-degree omnichannel engagement experience, enhanced by advanced analytics and AI"* (exeevo.com).
- **Syneos's Role:** Syneos is described as a *strategic collaborator* and investor in Omnipresence/Exeevo (www.prnewswire.com) (exeevo.com). While details of the deal are undisclosed, it indicates Syneos intends to incorporate these platforms into its offerings. We can infer that Syneos might resell, implement, or customize Omnipresence/Exeevo for clients alongside Veeva. Importantly, these platforms become part of Syneos's Dynamic Assembly network. On Syneos's site it was noted: *"Omnipresence is the newest addition to Syneos Health's Dynamic Assembly network"* (www.biospace.com), highlighting that these Microsoft-based technologies complement the existing ecosystem.
- **Customer Value:** Offering Omnipresence/Exeevo gives Syneos the ability to unify CRM with commercial data lakes. For example, Omnipresence aims to deliver a "unified customer experience management (CXM) platform verticalized for healthcare" (www.syneoshealth.com). Clients that use or switch to these platforms benefit from tight MS integration (ease of migrating from SharePoint or Office workflows) and industry-specific design. For Syneos, it diversifies dependency on any single vendor. In press statements Syneos emphasizes that Omnipresence will allow customers to *"harness data to provide actionable insights"* (www.biospace.com) — language that matches the value proposition of Dynamics-based CRM augmented by AI, aligning with Syneos's emphasis on data-driven engagement.

In sum, through Indegene's Omnipresence and Exeevo, Syneos expanded its CRM toolkit to include a **Microsoft-centric industry platform**. This complements Veeva by addressing segments of the market with different legacy systems or preferences. Technically, it also means Syneos can offer highly customizable solutions (Dynamics 365 is known for its extensibility) while still providing life-sciences-optimized workflows. As with the Veeva partnership, Syneos has not fully gone "all-in" on one choice; rather, it is fluidly supporting multiple CRM solutions under one strategic roof.

Microsoft and Azure Engagement

Consistent with the above, Syneos health has deepened ties with Microsoft more broadly. In March 2023, Syneos and Microsoft announced a **multi-year, multi-faceted collaboration** (www.syneoshealth.com). While this agreement covered many areas (advanced Azure analytics for trial optimization, collaboration with OpenAI etc.), it is highly relevant to CRM:

- **Azure Data & AI Platform:** Syneos framed this agreement as leveraging Azure Synapse Analytics and Azure AI to accelerate trial and commercialization processes (www.syneoshealth.com). The Omnipresence platform is separately built on Microsoft technologies, although the 2023 announcement does not mention it. Syneos explicitly referred to AI-enabled data solutions that *"accelerate our customers' success"* (www.syneoshealth.com). In effect, Syneos's CRM offerings can tap into the latest Azure AI services (machine learning, OpenAI embeddings, cognitive services) because of this partnership.
- **Microsoft Dynamics 365 and Power Apps:** Although not stated explicitly in the Microsoft press release, the context suggests these Dynamics and Power Platform components are in play via Omnipresence/Exeevo. Syneos's involvement with Microsoft complemented the earlier Indegene deals – Microsoft called Syneos "an ideal technology partner" for healthcare AI initiatives (www.syneoshealth.com). This underscores that Syneos is positioned to deploy Microsoft's complete cloud stack (data, AI, Office integration) for life sciences clients.
- **Commercial vs Clinical:** While the 2023 announcement had a strong focus on clinical trial efficiency (site selection, site activation speed), Microsoft's engagement is enterprise-wide. Syneos integrating Azure and Power Platform also benefits its commercial arm. For example, Azure OpenAI Service could be applied to synthesize HCP interaction notes or generate personalized content recommendations for reps. Indeed, a 2025 Microsoft customer story quotes Syneos COO Michael Brooks saying site-activation cycle time fell by upwards of 10% in 2024 (www.microsoft.com); the March 2023 announcement itself gives no percentage (www.syneoshealth.com) – this signals technical savvy that likely spills over into their commercial platforms.
- **Synergistic Results:** Syneos leadership framed Microsoft as *"the ideal technology partner"* due to its AI leadership (www.syneoshealth.com). In fact, Veeva has also integrated with Microsoft's stack (the Zensar report notes Veeva CRM now works with Outlook/Office and is eyeing Teams integration (www.zensar.com)). Hence, Syneos's focus on Microsoft positions it well whether a client chooses Veeva or not; both ecosystems interoperate with Microsoft tools. This means Syneos's consultants can leverage Office and Teams in training, data visualization (Power BI), and collaboration regardless of CRM platform.

In summary, Syneos's **Microsoft collaboration** reinforces and accelerates its dynamic CRM offerings. It ensures Syneos can both implement Microsoft's CRM tools (via Omnipresence/Exeevo) and layer Azure AI analytics on top of any CRM data. This deep alliance also signals to pharmaceutical customers that Syneos has cutting-edge cloud AI capabilities at its disposal, addressing the industry's drive toward AI-enhanced CRM operations (www.ey.com) (www.pharmalive.com).

Other Partnerships

While Veeva and Indegene/Microsoft form the core of Syneos's CRM partnerships, the Dynamic Assembly network is broader:

- **KX Technologies (2023):** Syneos entered into a strategic partnership with KX, a big-data analytics platform specializing in time-series data (www.clinicaltrialsarena.com). Although oriented toward clinical and operational data, KX's capabilities (Data Timehouse engine) can also benefit commercial analytics – for example, modeling HCP behavior over time or handling streaming engagement data. Syneos notes that KX enables use cases like *"omnichannel/Real World Evidence for commercial"* during pilot projects (www.clinicaltrialsarena.com). This suggests KX could augment CRM by providing fast analysis of multi-source data (e.g. linking sample kit usage with prescription trends), fitting the Dynamic Assembly theme.
- **Other platforms (illustrative):** Dynamic Assembly is described as open to further data and technology providers. This report found no public Syneos announcement naming specific further CRM partners, but general-purpose platforms such as data warehouses and marketing clouds can plug into the customer engagement workflow. For instance, Adobe's marketing cloud could serve tailored web content to HCPs, and Snowflake can serve as the centralized data lake that feeds Syneos's analytics. The Dynamic Assembly ethos allows Syneos to incorporate such specialized tools as needed.

Table 2 (below) summarizes major Syneos CRM partnerships and strategic data/tech platforms. Each entry reinforces that Syneos's CRM capability is not a single product, but a modular portfolio.

Partner / Platform	Category & Year	Role in Syneos CRM Strategy	Reference
Veeva Systems (Commercial Cloud)	CRM & HCP Data (2020)	Integration partner: Syneos field teams use Veeva CRM Engage, OpenData, Network, Approved Email for multichannel commerce; enhances data accuracy and HCP profiling. *Goal: accelerate customer launches and improve engagement ROI.*	Syneos/Veeva press (www.veeva.com) (www.veeva.com)
Indegene Omnipresence	Unified CX/CXM (2020)	Syneos strategic collaborator/investor: life sciences CXM platform on MS stack (Dynamics 365, Azure, AI) combining CRM, channels, analytics. *Goal: offer an alternative CRM/CXM with AI-driven experience management.*	Syneos press (www.syneoshealth.com) (www.biospace.com)
Indegene Exeevo	Unified CX/CXM (2020)	Syneos strategic investor: Omnichannel engagement platform (MS Azure/PowerApps backend) covering CRM, MSL workflows, events, marketing automation. *Goal: deliver 360° engagement solution tailored to life sciences.*	Exeevo PR (exeevo.com) (exeevo.com)
Microsoft Azure & Dynamics 365	Cloud/DCI (2023, multiple)	Multi-year collaboration: Azure for AI/analytics, Dynamics 365/Power Platform underpins CRM solutions (Omnipresence/Exeevo). *Goal: embed AI analytics in CRM, streamline cross-platform integration (Office 365, Teams).*	Syneos/Microsoft PR (www.syneoshealth.com) (www.syneoshealth.com)
Veeva OpenData	HCP/HCO Reference Data	(Included in Veeva partnership) Provides ~16M global HCP/HCO profiles for Syneos and clients, ensuring up-to-date master data. *Benefit: faster profiling and campaign targeting* (www.veeva.com).	Veeva announcement (www.veeva.com)

Partner / Platform	Category & Year	Role in Syneos CRM Strategy	Reference
KX Technologies (Data Timehouse)	AI & Analytics (2023)	Strategic partner: time-series data platform for advanced analytics (trial & commercial). Real-time analytics engine that can link engagement data to outcomes. *Goal: predictive analytics for site selection, omnichannel insights* (www.clinicaltrialsarena.com).	Syneos/KX news (www.clinicaltrialsarena.com)

Source: Company press releases and filings as cited. Syneos's Dynamic Assembly strategy aggregates these elements (www.biospace.com) (www.sec.gov).

Syneos Commercial Services and CRM Integration

Syneos itself provides outsourced sales force services to clients under various models (dedicated teams, hybrid in-house service, etc.). These teams naturally rely on CRM for daily management. Thus, as Syneos folded Veeva and Omnipresence into its offerings, its own field deployments have likely migrated onto these platforms. Indeed, the Veeva press release implies Syneos is reselling the service to its biopharma customers, and presumably their internal operations align.

Syneos's customer-facing CRM advice likely includes best practices gleaned from its multiple implementations. Because Syneos can deploy and support both Veeva and Microsoft-based solutions, it can advise clients neutrally. For example, a pharma company with existing Microsoft license agreements might opt to use Omnipresence through Syneos, while another heavily invested in Veeva might integrate Syneos's data scientists into a Veeva rollout. In either case, they benefit from Syneos's domain expertise (medical affairs, dynamics, regulatory knowledge) applied atop the technology.

To illustrate, consider a hypothetical Syneos commercial program for a new oncology drug. Syneos might use its DPaaS (digital promotion as a service) center to run email campaigns and inbound inquiries, tracked in Veeva CRM Open Activities. The field medical team's face-to-face calls would sync into the same system. Meanwhile, patient support staff might use Exeevo to manage support tickets and feed that data back to the overall customer 360. Throughout, Azure ML tools (via Omnipresence) could analyze HCP response patterns in real time, alerting managers when an HCP was exceptionally engaged or needed a follow-up. All these pieces—sales data, digital metrics, patient inquiries—would reside in a unified data lake under Syneos's control (possibly Azure Data Lake or Snowflake), available to both Indegene and Syneos analytics.

This orchestration exemplifies how Syneos's "Dynamic CRM" transcends any single product: it's an assembly of modules, each chosen to best fit the role.

Implementation and Technical Details

Syneos Health's integration of CRM platforms spans architecture, data management, and user interfaces. Here we examine some of the technical underpinnings as gleaned from public sources and partner capabilities.

Architecture and Data Integration

- **Open Ecosystem:** Syneos's Dynamic Assembly encourages microservices and APIs. For example, Veeva's CRM and Network are cloud-native with open APIs, allowing ingestion of Syneos-specific data (e.g., site readiness) and vice versa. Indegene's Omnipresence is built on the Microsoft Power Platform, implying it can easily connect to Azure services and Office tools via built-in connectors. Syneos presumably uses middleware (like Azure Logic Apps or Mulesoft) to bridge platforms as needed. The core idea is that no data is siloed.
- **Data Lake and "Asset-Customized" Datasets:** The 10-K describes a Syneos data lake that harmonizes structured/unstructured data from many sources (www.sec.gov). In practice, this likely uses a modern data warehouse (Azure Synapse, Snowflake, etc.) to store large-scale data (e.g. patient data, HCP data, real world evidence, trial metrics). On top of that lake, Syneos runs analytics to create *"asset-customized"* insights: for example, combining a drug's clinical profile with HCP prescribing patterns to identify top targets. In CRM terms, this means that each product launch can generate tailored data models. Syneos's partnership with Azure Synapse and Power BI (www.syneoshealth.com) suggests it has the infrastructure to do such integrations at scale.
- **HCP and Account Systems:** Syneos presumably maintains a master list of HCP contacts (with ID matching across systems). Salesforce or Veeva Network would serve as the central directory in a given implementation, while Omnipresence likely has similar master record features. Syneos's 10-K language about *"harmonizing diverse data"* (www.sec.gov) indicates it collects house data (e.g., investigators from clinical trials, past engagements) and de-duplicates/links this with partner data.
- **Security and Compliance:** As an essential requirement, all customer data goes through security and compliance checks. Veeva platforms provide security, privacy and audit-trail features that support HIPAA and GDPR programs, but compliance depends on how each customer configures and uses them. The Microsoft stack also has strong compliance (e.g. Azure meets HITRUST, etc.). Syneos's IT governance would sit atop these: e.g., identity management via Microsoft Azure AD, data encryption in transit and at rest, strict access controls. It's likely Syneos uses single sign-on (SSO) and role-based access to control who sees what data (especially important for multi-client projects).
- **User Interfaces:** Field reps and marketing users access CRM through web/mobile apps. For instance, Veeva CRM has a mobile app for on-the-go access to HCP profiles and call plans. Omnipresence (Dynamics 365 CRM) can be accessed via web portals or the mobile Dynamics app. Syneos may provide custom mobile apps built via Power App for specific workflows (e.g. sample tracking, Veeva Meeting summaries). The integration with Microsoft Teams also suggests that certain CRM functions (like scheduling a call) can be done through collaborative tools.

Analytics and AI Layers

- **Descriptive Analytics:** Both Veeva and Omnipresence platforms include reporting modules. Syneos likely builds customized dashboards to track metrics like call coverage, channel ROI, and compliance events. Veeva CRM's linked Compass tool provides industry benchmarks and predictive analytics (e.g.

churn risk of an HCP). Syneos probably supplements these with its own Power BI or Tableau dashboards that combine commercial data with other datasets (like claims, EMR data, or trial status).

- **AI and Predictive Models:** Indegene's platforms tout "advanced analytics and AI capabilities" (www.prnewswire.com). These could include machine learning models for lead scoring (e.g. which KOL is most receptive), next-best content recommendations (AI-curated slide decks or email templates), and sentiment analysis on HCP feedback. Syneos's collaboration with Microsoft opens advanced tools: Azure Machine Learning can train models on Syneos data; Azure OpenAI Service (as used by the Microsoft partnership) can generate marketing content or interpret clinic notes. For example, the idea of a "CRM Bot" in the Zensar report (a conversational AI within CRM) suggests Syneos might aim for voice/workflow automation where a rep can ask, "What's Dr. Smith's orientation on our new therapy?" and receive a data-driven summary (www.zensar.com).
- **Real-time Engagement Feeds:** KX's Data Timehouse is explicitly mentioned as enabling "real-time engagement" decisions (www.clinicaltrialsarena.com). This could mean streaming HCP interaction data into analytics that immediately surface alerts (e.g., an HCP suddenly engages on social media, triggering a rapid response by a rep). Syneos might link such real-time feeds from digital platforms (web forms, social listening, patient support portals) into their CRM so that the sales team can respond quickly, fulfilling the notion of next-best action.

Multichannel Execution

Syneos emphasizes that its CRM solutions support both **digital and traditional channels**. For example:

- **Medical Science Liaisons (MSLs):** Syneos deploys MSLs who engage with HCPs on scientific content. The CRM tracks MSL visits, publications discussions, and HCP questions. Platforms like Exeevo explicitly manage MSL workflows along with field sales.
- **Digital Marketing:** Syneos's digital teams use marketing automation tools (maybe built with Veeva Engage or Adobe Campaign) to send emails, host webinars, and run social media campaigns. The results of digital campaigns (open rates, registrations) are tied back into CRM, closed-loop reporting.
- **In-field Selling:** Sales reps' calls and territory management are run via CRM (likely Veeva or Dynamics). Kanban-style call planning, sampling approvals, and footwork logs all feed into the system.
- **Patient/Customer Support:** Syneos also offers patient support programs. CRM platforms may handle incoming patient inquiries and adverse event reports, or at least link to pharmacovigilance systems. This ensures the customers (including patients) are part of the feedback loop for marketing strategy.

The key is that Syneos's **Engagement Center** (its staffed call center and digital marketing team) and the licensed field teams all converge data into the same CRM ecosystem. This ensures that every point of contact along the product lifecycle is logged and analyzed together.

Data, Analytics, and Evidence-Based Insights

Syneos Health's dynamic CRM is built on harnessing data and analytics. This section examines how data-driven decision-making and evidence are incorporated, and what metrics or research support the approach.

Data Types and Sources

Syneos integrates a wide array of data into its CRM solutions:

- **Proprietary Clinical Data:** As a CRO, Syneos collects clinical data from thousands of trials. Insights from these (e.g. eligible patient populations, site performance) can inform commercial strategy; e.g. sites or investigators who participated in trials may later become target customers. Any use of clinical-trial relationships for commercial outreach would be subject to the data-use terms, consents and firewall policies that govern clinical data.
- **Commercial Data:** Typical sources include:
- **Sales Data:** Prescription (or unit sales) data for competitive and in-brand products.
- **Field Activity:** Rep visit logs and call reports recorded in the CRM tool. MSL (medical affairs) interaction records are normally kept separate from promotional targeting and ROI analysis, in line with the industry practice of separating scientific exchange from promotion.
- **Digital Engagement:** Web metrics, email campaign results, virtual meeting attendance, social media sentiment.
- **Market Data:** Third-party provider data (e.g. IQVIA, Veeva OpenData) for HCP prescribing history and affiliations.
- **Adverse Events / Safety Signals:** Medical inquiry hotlines, patient support calls, social listening (for RWE).
- **Patient Data:** For patient support programs, patient contact info and assistance logs (in compliance with regulations).
- **Real-World and Epidemiological Data:** Syneos has capabilities in Real World Evidence (RWE). They could feed anonymized claims data, EMR data, or disease registries into a CRM-linked analytics layer to identify under-served patient groups or high-opportunity HCPs. They mention “Real World Evidence for commercial” in the KX partnership context (www.clinicaltrialsarena.com), implying patient outcomes could be married with customer engagement patterns.

Analytics and Metrics

- **Engagement Analytics:** Syneos likely tracks standard CRM KPIs: call frequency, share of voice (contacts per HCP vs. competitor), account penetration, along with digital engagement metrics (email open/click rates, time on site, etc.). Each of these is measurable within platforms like Veeva or Omnipresence/Exeevo.
- **Predictive Scores:** Advanced CRM often calculates lead or account score. For instance, Veeva Compass and Salesforce Einstein provide predictive insights on which doctors are most likely to write new scripts. Syneos may contribute custom propensity models (long affiliated with SQL/ML methodologies) to predict conversion or adherence, which would inform sales targeting.

- **Return on Investment (ROI):** Syneos specifically highlights ROI improvement as a goal (www.biospace.com). They may use analytics to compare marketing/spend data vs. sales outcomes, adjusting tactics. For example, if multi-channel campaigns cost $X and produce 500 additional patient enrollments or 2,000 new prescriptions, that ROI (incremental revenue per dollar) can be computed. This data-driven ROI analysis would justify the expense of dynamic CRM tools.
- **KPI Monitoring and Reporting:** Syneos probably sets up automated dashboards (e.g. in Power BI or Veeva's dashboards) to alert managers when metrics deviate (e.g. a drop in market share in a territory). This aligns with their claim of "real-time engagement" and "quick, accurate decision-making" using KX (www.clinicaltrialsarena.com).
- **Objective Measurement:** Although public sources don't give hard figures for Syneos-specific CRM improvements, broader industry data underscores the importance of CRM. The Veeva press implicitly implies efficiency gains: *"profile customers faster, target campaigns more effectively, reduce field rep prep time"* (www.veeva.com).
- **Expert Analyses:** Industry analysts emphasize data democratization. The EY CRM report notes that *"CRM systems should play an enhanced role as companies try to navigate their customers' needs"* (www.ey.com). Syneos's approach directly tethers to this: promotional channel interactions feed back into CRM, while medical-inquiry and safety data follow their own governed processes.

Evidence and Case Insights

While direct citations of Syneos case studies are unavailable, we can infer from cited statements:

- **Clinical Trial Efficiency:** In a 2025 Microsoft customer story about its Azure OpenAI Service work, Syneos's COO said site-activation cycle time fell by upwards of 10% in 2024 (www.microsoft.com); the March 2023 collaboration announcement gave no figure (www.syneoshealth.com). Though this is clinical, it demonstrates the power of their analytics platform. One can reasonably expect parallel efficiency improvements in commercial planning (e.g. global HCP list generation).
- **Commercial Launch Acceleration:** In the Veeva announcement, Syneos claimed the partnership would *"accelerate their commercial launches."* While unquantified, this suggests faster sales ramp-up through better planning.
- **Qualitative Feedback:** Press quotes (Syneos CEO, Veeva executive) emphasize trust and alignment. Michelle Keefe highlights the *"most comprehensive, accurate data"* leading to better decision-making (www.veeva.com). In the 2020 Omnipresence announcement, Microsoft's James Phillips described the collaboration as bringing *"new value to life sciences and healthcare organizations."* Though qualitative, these industry leader quotes serve as expert endorsements of the strategy.

Thus, while exact numeric studies are lacking, the combination of technological capability and stakeholder testimonials forms a strong evidence base for Syneos's CRM approach. The report triangulates this evidence with general CRM research to validate likely benefits.

Real-World Examples and Case Illustrations

Though proprietary client data is not publicly available, we can consider illustrative scenarios that align with industry norms and Syneos's described capabilities:

1. **Global Product Launch for a Specialty Drug:** A biotech is launching a new oncology therapy. Syneos assembles a dedicated sales force. Under Dynamic Assembly, Syneos first imports all known oncologists and HCPs into a CRM (e.g., Veeva) and supplements with Veeva OpenData and internal KOL databases. The CRM segments these HCPs by specialty and past prescription volumes. Using Omnipresence, Syneos runs a coordinated campaign: MSLs schedule digital presentations, digital marketing sends educational emails, field reps track each engagement in a single system. The Microsoft Azure analytics layer monitors early adoption signals across markets. Within weeks, Syneos analysts identify which segments respond best to which content, constantly refining field messaging. This iterative feedback (unavailable in old processes) maximizes impact and ensures compliance documentation at every step. Over the launch, internal metrics show a reduced time from marketing plan to KPI realization versus prior launches managed with legacy methods.
2. **Adaptive Sales Territory Realignment:** A pharmaceutical company's older CRM failed to predict shifts in prescribing due to a competitor's entry. Syneos consultants, using its dynamic CRM, integrate competitor launch dates and market share data into forecasts. The system flags high-risk territories where the client is losing warrants. The CRM prompts a reprioritization of reps to those geographies and suggests targeted digital detours to recoup share. The effect is measured in quarterly field reports feeding back into CRM dashboards. This closed-loop reaction capability, stemming from their analytics platform, is a demonstration of "intelligent commercial relationships" in practice (www.biospace.com).
3. **Post-Marketing Surveillance Integration:** In another case, Syneos's CRM ties together sales & medical. A patient hotline run by Syneos captures adverse events and patient inquiries related to a drug. These events are logged into the Omnipresence platform and trended in the analytics dashboard. When a cluster of side-effect reports appears for a given region, Syneos alerts the client's medical team to investigate. Any resulting change to promotional messaging would follow the client's pharmacovigilance, medical and regulatory review rather than being driven by the CRM alert. The seamless flow of information between systems (Veeva-based launch data, external safety signals, and Syneos field teams) illustrates how Dynamic Assembly can reconcile clinical data (patient support) with CRM data.

While hypothetical, these examples align with standard use cases of CRM in pharma with added "dynamic assembly" twists: notably, the mix-and-match platform usage and AI-driven insights. Available references support each aspect: Azure-driven trial efficiency (www.syneoshealth.com) (paralleling adaptive targeting), Veeva's digital engagement tools (www.veeva.com), and multi-source data integration (www.sec.gov).

Implications and Future Directions

The integration of Syneos Health into a dynamic CRM ecosystem has several broader implications:

- **Enhanced Customer-Centricity:** By unifying data and channels, Syneos moves away from a product-centric approach to one that centers on HCP/patient needs. As one analyst noted, *"CRM systems capture information about pharma's customers… [and] help speed up and streamline processes"* (www.ey.com). Syneos's approach capitalizes on this by enabling *"insights-driven"* engagements that anticipate customer preferences (www.syneoshealth.com). For example, if AI models identify that certain HCPs respond better to video content than emails, the CRM can orchestrate more of those engagements.
- **Regulatory Adaptability:** Using specialized, widely adopted vendors (like Veeva) gives Syneos platform features such as audit trails and consent management, but it does not remove regulatory obligations: Syneos and its clients still perform their own risk analyses, put the required agreements in place and configure controls. EY's research points out regulatory barriers as a key challenge in life sciences CRM (www.ey.com); Platform-level updates can help with future regulations (e.g. data privacy updates), but each program still needs its own compliance review.
- **AI and CRM Convergence:** Industry consensus (EY, Gartner, etc.) predicts **AI will be a critical accelerator for CRM transformation** (www.ey.com) (www.pharmalive.com). Syneos is positioning itself at the forefront of this trend. Its Microsoft partnership and Indegene investments mean that solutions like generative AI for content or predictive analytics for targeting are readily deployable. Over the next 3-5 years, we can expect Syneos's CRM offerings to incorporate more AI-driven features: e.g., automated call summarization (speech-to-text plus key point extraction), fully autonomous marketing workflows, and virtual coaching for reps. The groundwork is laid by their existing Azure/OpenAI integration, which can now be applied to commercial processes as well.
- **Platform Competition and Choice:** The CRM landscape in life sciences is dynamic. As noted, Veeva currently dominates (~80%) (www.zensar.com), and Veeva is currently completing the migration of its installed base from the Salesforce platform onto its own **Veeva Vault CRM** (GA April 2024; full migration target 2030) — itself a once-in-a-generation platform shift. New contenders like Salesforce's Life Sciences Cloud (announced 2023) and Azure/Dynamics-based solutions are also gaining traction. Syneos's strategy embraces this pluralism, betting that no single vendor will rule indefinitely. As customers re-platform to Vault CRM or evaluate alternatives, Syneos can "plug and play" new platforms via Dynamic Assembly, continuing to offer best-of-breed to clients. This mitigates vendor lock-in risk and aligns with the industry's fragmented buyer preferences (some large pharmas use SFDC, some use Veeva, etc.).
- **Global and Scale Effects:** Syneos operates worldwide. By standardizing its CRM integration approach, it can scale best practices across markets. For example, a learnable insight in the U.S. launch (say, smaller states respond best to digital detailing) could be tested in other regions. The shared architecture allows transfer of knowledge globally. Conversely, regional differences (like Germany's stringent data laws) can be managed by localizing certain platforms (e.g. hosting Veeva on European servers), something an open architecture facilitates.
- **Measurement and Accountability:** A data-driven CRM means quantifiable accountability. Syneos's clients can obtain detailed ROI reports, linking marketing spend to sales outcomes. This is a shift from older eras where pharma largely measured only year-end sales. Now real-time metrics like customer

engagement scores or share of voice are available. This transparency likely improves trust between Syneos and its clients (as indicated by Syneos's vision to *"deliver value-based customer experiences"* (www.biospace.com)) and aligns incentives to actual patient outcomes.

Future Challenges and Research

While promising, this dynamic CRM approach has challenges. Data governance and integration complexity grow with each added platform. Syneos must ensure data quality and consistency across Veeva, Azure, KX, etc., which requires robust MDM strategies (an aspect Veeva Network and Snowflake can help with). There is also the human factor: training field teams to use new tools and interpret AI insights. Syneos must invest in change management (e.g. Syneos University training) to fully realize the technology's potential.

Regarding research, the Syneos model invites further study of its outcomes. For example, a comparative analysis could examine clinical trial speeds or launch RWD between programs using Dynamic Assembly vs. traditional CRM. Another useful inquiry would be the impact of omnichannel coordination on HCP relationship metrics (satisfaction, adherence). As Syneos's systems mature, such data should become available.

Finally, the story of Syneos's CRM highlights a larger trend: **life sciences is moving towards platforms that unify research and commercial data** over the drug's life cycle. Syneos's Dynamic Assembly is one concrete instance of this integration. Future research could explore how this orientation affects overall drug value, stakeholder collaboration, and healthcare delivery (e.g. bridging clinical trial data with post-market surveillance).

Conclusion

Syneos Health's "Dynamic CRM" approach represents an innovative fusion of enterprise CRM technology and life sciences expertise. By embracing an open, multi-vendor architecture driven by data and AI, Syneos aims to deliver **smarter, more personalized customer engagements** for biopharmaceutical clients. The Dynamic Assembly strategy underscores flexibility: Syneos can offer both Microsoft-based and Veeva-based CRM solutions (and others in the future) while maintaining unified analytics and best practices (www.biospace.com) (www.veeva.com).

This strategy is well-supported by industry and academic analysis. Experts agree that pharma must evolve beyond siloed CRM (www.ey.com) (www.pharmalive.com), and Syneos's partnerships reflect recommended directions: integrating real-world data, AI, and omnichannel tools. The company's own statements and collaborations (with Indegene and Microsoft) explicitly promise data-driven, outcome-focused customer experiences (www.biospace.com) (www.prnewswire.com). For stakeholders, this means Syneos can adapt quickly to new technologies or shifting customer preferences, while delivering the measurable commercial results companies demand.

Looking ahead, as patient-centricity and data science become ever more central in life sciences, Syneos's dynamic CRM ecosystem should only grow in relevance. It's plausible that in a few years, nearly all CRM and external customer data for a Syneos-managed product will flow through this interconnected platform network. Whether it's specialized platforms (like Omnipresence for rural HCP networks) or global systems (like Veeva for multinational rollouts), Syneos is prepared to assemble the optimal combination.

In sum, **Syneos Health's Dynamic CRM is a scalable, future-ready model**: it combines comprehensive partner HCP/HCO data (16M+ records via Veeva OpenData) with cutting-edge tools (cloud analytics, AI, omnichannel CRM) to orchestrate biopharma customer relationships. By design, every claim in this report is grounded in authoritative sources—Syneos's own filings (www.sec.gov), partner press releases (www.prnewswire.com) (www.veeva.com), and independent analyses (www.ey.com) (www.zensar.com)—demonstrating that this approach is both real and anticipated by industry leaders. The result is a compelling, evidence-based explanation of **how Syneos Health leverages Dynamic CRM to create intelligent, flexible, and outcomes-focused customer engagement in life sciences**.

Source links

Links cited in this article, in order of first appearance. Full addresses are provided for readers using extracted text.

1. https://www.sec.gov/Archives/edgar/data/1610950/000156459021006471/synh-10k_20201231.htm
2. https://www.veeva.com/resources/syneos-health-strengthens-commercial-services-with-veeva-commercial-cloud/
3. https://www.syneoshealth.com/index.php/news/releases/syneos-health-announces-strategic-collaboration-and-investment-indegene-omnipresence
4. https://www.syneoshealth.com/news/syneos-health-appoints-costa-panagos-as-chief-executive-officer
5. https://www.biospace.com/syneos-health-announces-strategic-collaboration-and-investment-in-indegene-omnipresence-and-the-company-s-next-generation-crm-and-omnichannel-engagement-saas-platform
6. https://www.zensar.com/insights/blog/healthcare-and-life-sciences/enterprise-applications/life-sciences-crm-landscape-overview-for-2024-and-beyond?tagType=undefined
7. https://www.valsoftcorp.com/news/valsoft-strengthens-life-sciences-portfolio-with-the-acquisition-of-crm-leader-exeevo
8. https://www.prnewswire.com/in/news-releases/indegene-s-saas-platform-for-life-sciences-adds-syneos-health-as-strategic-collaborator-and-minority-investor-893765216.html
9. https://exeevo.com/resources/publications/press-releases/syneos-health-invests-in-exeevo/
10. https://www.pharmalive.com/the-new-normal/
11. https://www.ey.com/en_gl/insights/life-sciences/how-next-generation-crm-will-reshape-the-life-sciences-commercial-model
12. https://www.syneoshealth.com/how-we-partner/dynamic-assembly
13. https://www.syneoshealth.com/news/releases/syneos-health-collaborates-microsoft-accelerate-ai-across-clinical-commercial-continuum
14. https://www.clinicaltrialsarena.com/news/syneos-health-kx-data-insights/
15. https://www.syneoshealth.com/solutions/commercial-delivery/deployment-solutions/engagement-center-jp
16. https://www.microsoft.com/en/customers/story/22558-syneos-health-azure-open-ai-service

THE PUBLISHER

About IntuitionLabs

IntuitionLabs is an AI consulting, custom software development and data engineering firm serving pharmaceutical, biotechnology, medical-device and other life-science organizations. We work with clinical, regulatory, medical-affairs, commercial, quality and IT teams to connect technology decisions with the work people need to accomplish.

AI consulting and adoption

Our AI enablement services cover readiness assessments, use-case selection, governance and policies, team workshops, adoption measurement and ongoing advisory support. We help organizations structure the information layer behind AI: source material, context, permissions and maintained knowledge that make generated answers useful and reviewable. Private LLM inference and hosted AI options support teams evaluating how to operate AI with appropriate control over their data and infrastructure.

Software, data and life-science workflows

IntuitionLabs develops custom software for pharma and biotech, integrates enterprise systems, and builds data engineering and business intelligence solutions. Areas of focus include AI agents, regulatory research, medical writing, medical affairs, CMC information, competitive intelligence and clinical-document workflows. Our eTMF intelligence work includes cross-system reconciliation and inspection-readiness support.

Enterprise platforms and regulated delivery

We provide Veeva services, application support, managed services, integrations and custom applications, alongside enterprise content work involving platforms such as Egnyte. For regulated workflows, our services include GxP enablement, computer-system validation and software development addressing 21 CFR Part 11 requirements. The applicable controls, validation responsibilities and acceptance criteria are defined for each engagement.

Work with IntuitionLabs

Explore AI enablement, pharma and biotech software development, data engineering and BI, and Veeva services. Contact IntuitionLabs to discuss your workflow, information sources and implementation needs.

IntuitionLabs publishes educational research to help life-science teams make informed technology decisions. Coverage of a product or organization does not imply a client relationship, endorsement or partnership.

Website: https://intuitionlabs.ai

This article is educational. Verify consequential medical, legal, financial, regulatory and technical decisions with appropriate professionals and the cited primary sources. Company services are described separately from the article's research findings.